← Oncology Approval Tracker

FDA DECISION ·

Vitrakvi

larotrectinib · Bayer Healthcare Pharmaceuticals

Traditional approvalTraditional conversionNTRK fusion-positive solid tumors
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults and children with NTRK fusion-positive solid tumors without a known acquired resistance mutation, when disease is metastatic or surgery would likely cause severe morbidity, and no satisfactory alternatives exist or disease has progressed following treatment.

LAMPGEN ANALYSIS

Why it matters

Additional clinical follow-up supported traditional approval of this tumor-agnostic indication originally authorized in 2018.

What research teams should watch

Review the actual fusion and prior treatment or surgical assessment, and preserve continuity between molecular testing and referral.

PRIMARY RECORDS

Sources